Merck signs MoU with CSIR-IICT to strengthen industry-academia ties

The collaboration will foster joint research initiatives, scientific knowledge exchange, and innovation

Lilly’s oral GLP-1 drug Orforglipron outperforms Semaglutide in phase 3 diabetes trial

Based on the cumulative data from ACHIEVE-1 through ACHIEVE-5, Lilly plans to submit orforglipron for FDA approval for the treatment of type 2 diabetes by the end of the second quarter

Agilus’s Idylla claims to deliver cancer mutation results in just 3 hours

Advanced molecular diagnostics solution enables rapid, high-accuracy biomarker detection for precision oncology

FDA expands Pfizer’s HYMPAVZI approval

Broadening access for children & patients with inhibitor-complicated hemophilia

AbbVie showcases broad blood cancer pipeline at EHA 2026 with 21 presentations

The company will present 21 oral and poster presentations spanning investigational and approved therapies

Mariska Hargitay launches Bristol Myers Squibb's Myeloma Awareness Campaign

The campaign places renewed focus on a disease that remains incurable despite major scientific advances

Lilly’s “triple agonist” drug delivers striking weight loss & broad health gains in late-stage trials

Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems

Merck appoints Clara Sattler de Sousa e Brito and Robert Machinek to key leadership roles

Clara Sattler de Sousa e Brito to lead discovery solutions from Q3 2026, while Robert Machinek takes over as Head of Strategy & Business Development

Lupin partners with LABORATORIOS ERN to launch Luforbec in Spain

Collaboration combines Lupin’s inhaler manufacturing capabilities with ERN’s strong commercial presence to expand access to respiratory care

Novo Nordisk’s CagriSema delivers strong Phase 3 results across REIMAGINE diabetes trials